Refine
Year of publication
Document Type
- Article (35)
Has Fulltext
- yes (35)
Is part of the Bibliography
- no (35)
Keywords
- MLL (6)
- Cell biology (4)
- acute leukemia (3)
- AF4 (2)
- Cancer (2)
- IKZF1 (2)
- MLL-r leukemia (2)
- machine learning (2)
- 11q23/MLL rearrangements (1)
- 5-lipoxygenase (1)
- AF4–MLL (1)
- ALL (1)
- AML (1)
- ARID5B (1)
- Acute leukemia (1)
- Acute myeloid leukemia (1)
- Akute Leukämie (1)
- Biochemistry (1)
- Biophysical chemistry (1)
- CEBPE (1)
- COBL (1)
- COVID-19 (1)
- CPE (1)
- Cancer models (1)
- Chromosomal translocations (1)
- Chromosomale Translokation (1)
- Diagnostik von MLL Translokationen (1)
- EGR1/2/3 (1)
- Functional aspects of cell biology (1)
- Fusion proteins (1)
- Gene (1)
- Genetic engineering (1)
- Genetics (1)
- HDAC (1)
- HOXA profile (1)
- HOXB4 (1)
- Haploidentical stem cell transplantation (1)
- IRX1 (1)
- Infant leukemia (1)
- KIR (1)
- KMT2A (1)
- LASP1 (1)
- Leukaemia (1)
- MAML2 (1)
- MLL fusion proteins (1)
- MLL-Baby (1)
- MLL-r acute leukemia (1)
- Minimal Residual Disease (MRD) (1)
- Minimal residual disease (1)
- Molecular biology (1)
- Molecular mechanisms of cancer (1)
- Molekulare Therapie (1)
- NEBL (1)
- Oncoprotein activation (1)
- RAG (1)
- RNA-templated DNA repair (1)
- Ribosome biogenesis (1)
- SARS-CoV-2 (1)
- SL1 (1)
- SMAP1 (1)
- Secondary mutations (1)
- Structural biology (1)
- Taspase1 (1)
- Translocation partner genes (1)
- acute lymphoblastic leukemia (1)
- biomarker (1)
- calcitriol (1)
- cell cycle (1)
- chemogenomics (1)
- chromosomal translocations (1)
- corona virus (1)
- drug screening (1)
- genetic rearrangements (1)
- high content imaging (1)
- high throughput (1)
- infants (1)
- infection model (1)
- leukemia; solid tumors (1)
- live cell imaging (1)
- pSer domain (1)
- phenotypic screening (1)
- premature transcript termination (1)
- recurrent chromosomal translocations (1)
- relapse (1)
- t(4;11) leukemia (1)
- therapy (1)
- translocation partner genes (1)
- treatment outcome (1)
- дети первого года жизни (1)
- исходы терапии (1)
- острые лейкозы (1)
- перестройки 11q23/MLL (1)
Institute
Over the last 15 years the Diagnostic Center of Acute Leukemia (DCAL) at the Frankfurt University has diagnosed and elucidated the Mixed Lineage Leukemia (MLL) recombinome with >100 MLL fusion partners. When analyzing all these different events, balanced chromosomal translocations were found to comprise the majority of these cases (~70%), while other types of genetic rearrangements (3-way-translocations, spliced fusions, 11q inversions, interstitial deletions or insertion of chromosomal fragments into other chromosomes) account for about 30%. In nearly all those complex cases, functional fusion proteins can be produced by transcription, splicing and translation. With a few exceptions (10 out of 102 fusion genes which were per se out-of-frame), all these genetic rearrangements produced a direct MLL fusion gene, and in 94% of cases an additional reciprocal fusion gene. So far, 114 patients (out of 2454 = ~5%) have been diagnosed only with the reciprocal fusion allele, displaying no MLL-X allele. The fact that so many MLL rearrangements bear at least two fusion alleles, but also our findings that several direct MLL fusions were either out-of-frame fusions or missing, raises the question about the function and importance of reciprocal MLL fusions. Recent findings also demonstrate the presence of reciprocal MLL fusions in sarcoma patients. Here, we want to discuss the role of reciprocal MLL fusion proteins for leukemogenesis and beyond.
Chromosomal translocations (CTs) are a genetic hallmark of cancer. They could be identified as recurrent genetic aberrations in hemato-malignancies and solid tumors. More than 40% of all “cancer genes” were identified in recurrent CTs. Most of these CTs result in the production of oncofusion proteins of which many have been studied over the past decades. They influence signaling pathways and/or alter gene expression. However, a precise mechanism for how these CTs arise and occur in a nearly identical fashion in individuals remains to be elucidated. Here, we performed experiments that explain the onset of CTs: (1) proximity of genes able to produce prematurely terminated transcripts, which lead to the production of (2) trans-spliced fusion RNAs, and finally, the induction of (3) DNA double-strand breaks which are subsequently repaired via EJ repair pathways. Under these conditions, balanced chromosomal translocations could be specifically induced. The implications of these findings will be discussed.
Phenotypical screening is a widely used approach in drug discovery for the identification of small molecules with cellular activities. However, functional annotation of identified hits often poses a challenge. The development of small molecules with narrow or exclusive target selectivity such as chemical probes and chemogenomic (CG) libraries, greatly diminishes this challenge, but non-specific effects caused by compound toxicity or interference with basic cellular functions still pose a problem to associate phenotypic readouts with molecular targets. Hence, each compound should ideally be comprehensively characterized regarding its effects on general cell functions. Here, we report an optimized live-cell multiplexed assay that classifies cells based on nuclear morphology, presenting an excellent indicator for cellular responses such as early apoptosis and necrosis. This basic readout in combination with the detection of other general cell damaging activities of small molecules such as changes in cytoskeletal morphology, cell cycle and mitochondrial health provides a comprehensive time-dependent characterization of the effect of small molecules on cellular health in a single experiment. The developed high-content assay offers multi-dimensional comprehensive characterization that can be used to delineate generic effects regarding cell functions and cell viability, allowing an assessment of compound suitability for subsequent detailed phenotypic and mechanistic studies.
Dimerization of Taspase1 activates an intrinsic serine protease function that leads to the catalytic Thr234 residue, which allows to catalyze the consensus sequence Q−3X−2D−1⋅G1X2D3D4, present in Trithorax family members and TFIIA. Noteworthy, Taspase1 performs only a single hydrolytic step on substrate proteins, which makes it impossible to screen for inhibitors in a classical screening approach. Here, we report the development of an HTRF reporter assay that allowed the identification of an inhibitor, Closantel sodium, that inhibits Taspase1 in a noncovalent fashion (IC50 = 1.6 μM). The novel inhibitor interferes with the dimerization step and/or the intrinsic serine protease function of the proenzyme. Of interest, Taspase1 is required to activate the oncogenic functions of the leukemogenic AF4-MLL fusion protein and was shown in several studies to be overexpressed in many solid tumors. Therefore, the inhibitor may be useful for further validation of Taspase1 as a target for cancer therapy.
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion. They achieved a clinical remission under conventional chemotherapy but relapsed shortly after end of therapy. Both had a history of invasive mycoses (one had possible pulmonary mycosis, one systemic candidiasis). Because no HLA-identical donor was available, a haploidentical transplantation was performed in both cases. Using a specially designed PCR method for the assessment of minimal residual disease (MRD), based on the quantitative detection of the individual chromosomal breakpoint in the MLL gene, all patients achieved complete and persistent molecular remission after transplantation. The immune reconstitution after transplantation is described in terms of total CD3+/CD4+, CD3+/CD8+, CD19+, and CD16+/CD56+ cell numbers over time. The KIR and HLA genotypes of donors and recipients are reported and the possibility of a KIR-mediated alloreactivity is discussed. This report illustrates that haploidentical transplantation may offer a chance of cure without chronic graft-versus-host disease in situations where no suitable HLA-identical donor is available even in a high-risk setting and shows the value of MRD monitoring in the pre- and posttransplant setting.